Font Size: a A A
Keyword [Adjuvants]
Result: 81 - 100 | Page: 5 of 6
81. One-pot Synthesis Of Antigen-Conjugated Gold Nanoparticles And The Application As Vaccine Adjuvants
82. Comparison Of The Clinical Effects Of Nalbuphine Versus Ketorolac As Adjuvants To Local Wound Infiltration Anesthesia In Open Colorectal Surgery
83. Screening And Identification Of Anti-tumor Immune Adjuvants Based On RMBP-NAP
84. Impact of immuno-adjuvants on anti-lymphoma vaccine efficacy
85. Pluronic block copolymers for non-viral gene therapy
86. Evaluation of vaccine adjuvants as immunomodulators in pulmonary disease
87. In vitro and in vivo evaluation of novel biodegradable polymer adjuvants for vaccine delivery
88. Modulation of the immune response at systemic and mucosal sites by DNA vaccine adjuvants in HIV and influenza models
89. Evaluation of adjuvants and route of immunizations on the immune response to biodefense antigens
90. Recombinant protein vaccine candidates: A systematic approach to preformulation development and the effects of adsorption to aluminum salt adjuvants
91. Exosomes as endogenous adjuvants
92. Molecular and cellular signatures of phytol derivatives and the small intestinal submucosa in shaping immune responses to Staphylococcus aureus
93. Expeditious synthesis of hymenialdisine and its analogs and their evaluation as adjuvants in cancer therapy
94. Potentiation of the immune response with aluminum-containing adjuvants: I. Distribution of adsorbed antigen in mono-valent and combination vaccines; II. Role of antigen adsorption in antigen internalization by dendritic cells
95. Self-Assembled Antibody Nanorings as Prosthetic Antigen Receptors for Redirecting T Cells against Tumor Cells and as Platform for Delivery of Vaccine Adjuvants for Cancer Immunotherapy
96. Enhancement of cancer vaccine efficacy via nanoparticle or molecular-based adjuvants
97. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microsphere
98. Rational vaccine design through the use of molecular adjuvants
99. Consensus GII.4 virus like particles; a vaccine candidate biophysical characterization, stabilization, and adjuvants binding studies
100. IAP inhibitors as novel immune adjuvants for scaffold based cancer vaccines
  <<First  <Prev  Next>  Last>>  Jump to